1. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. (December 2017) Authors: Litton, J.; Scoggins, M.; Ramirez, D.; Murthy, R.; Whitman, G.; Hess, K.; Adrada, B.; Moulder, S.; Barcenas, C.; Valero, V.; Gomez, J.; Mittendorf, E.; Thompson, A.; Helgason, T.; Mills, G.; Piwnica-Worms, H.; Arun, B. Journal: NPJ breast cancer Issue: Volume 3(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗